Search

Displaying results 8371 - 8380 of 8547 in total
  1. Drug

    Cyclohexanone

    go.drugbank.com/drugs/DB02060
    Experimental

    Cyclohexanone (also known as oxocyclohexane, pimelic ketone, ketohexamethylene, cyclohexyl ketone or ketocyclohexane) is a six-carbon cyclic molecule with a ketone functional group.

  2. Drug

    Mirfentanil

    go.drugbank.com/drugs/DB09175
    Experimental

    At high doses, it exhibits analgesic activity which is not fully reversed by opioid antagonists, suggesting that the drug has both opioid and non-opioid mechanisms of action.

  3. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31.

  4. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

  5. Drug

    Vicadrostat

    go.drugbank.com/drugs/DB21693
    Investigational

    Vicadrostat has a monoisotopic molecular weight of 317.06 Da.

  6. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

  7. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    Nevadistinel has a monoisotopic molecular weight of 274.13 Da.

  8. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous

  9. Drug

    5'-Guanosine-Diphosphate-Monothiophosphate

    go.drugbank.com/drugs/DB01864
    Experimental

    A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific

  10. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this